News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,275 Results
Type
Article (13778)
Company Profile (101)
Press Release (251396)
Section
Business (88083)
Career Advice (469)
Deals (15352)
Drug Delivery (67)
Drug Development (36604)
Employer Resources (49)
FDA (6299)
Job Trends (6201)
News (150270)
Policy (14029)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Adcomms (6)
Allergies (32)
Alliances (23219)
ALS (36)
Alzheimer's disease (385)
Antibody-drug conjugate (ADC) (36)
Approvals (6336)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4375)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (578)
Cardiovascular disease (70)
Career advice (410)
Career pathing (11)
CAR-T (20)
Cell therapy (83)
Cervical cancer (4)
Clinical research (30870)
Collaboration (323)
Compensation (132)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (116)
Cystic fibrosis (35)
Data (595)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1318)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32077)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37415)
Executive appointments (355)
FDA (6689)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (204)
Gene editing (37)
Generative AI (8)
Gene therapy (98)
GLP-1 (339)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3569)
Huntington's disease (4)
IgA nephropathy (10)
Immunology and inflammation (34)
Indications (12)
Infectious disease (789)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (44)
Interviews (59)
IPO (5879)
IRA (29)
Job creations (2050)
Job search strategy (376)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3431)
Liver cancer (19)
Lung cancer (78)
Lymphoma (51)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1279)
Medtech (1281)
Mergers & acquisitions (9659)
Metabolic disorders (246)
Multiple sclerosis (19)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (553)
NextGen: Class of 2025 (1593)
Non-profit (602)
Northern California (673)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (42)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28882)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8032)
Phase II (13060)
Phase III (11725)
Pipeline (398)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3207)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2633)
Recruiting (17)
Regulatory (10085)
Reports (14)
Research institute (566)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (690)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1632)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6820)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (80)
Last 7 days (262)
Last 30 days (969)
Last 365 days (12089)
2025 (2981)
2024 (12507)
2023 (14250)
2022 (19565)
2021 (20076)
2020 (19041)
2019 (14908)
2018 (11728)
2017 (13898)
2016 (13141)
2015 (15487)
2014 (12423)
2013 (10595)
2012 (11398)
2011 (11928)
2010 (10890)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20090)
Australia (2603)
California (1628)
Canada (871)
China (228)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39369)
Florida (303)
Georgia (35)
Idaho (9)
Illinois (183)
India (14)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1403)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (715)
New Mexico (7)
New York (474)
North Carolina (377)
North Dakota (2)
Northern California (673)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (410)
Puerto Rico (8)
Rhode Island (7)
South America (502)
South Carolina (2)
Southern California (690)
Tennessee (34)
Texas (218)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
265,275 Results for "jazz pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 5, 2025
·
14 min read
Lung cancer
Jazz Touts Survival Benefit for First-Line Maintenance Therapy in SCLC
Jazz Pharmaceuticals contends that its alkylating agent Zepzelca significantly improved both overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, when used as a front-line maintenance therapy with Roche’s Tecentriq.
October 16, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming June 2024 Investor Conferences
Jazz Pharmaceuticals plc announced that Company management will participate in the following investor conferences.
May 29, 2024
·
1 min read
Mergers & acquisitions
Jazz Expands Cancer Expertise With $935M Chimerix Buy
At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.
March 5, 2025
·
2 min read
·
Tristan Manalac
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas.
May 1, 2024
·
1 min read
Drug Development
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint
Jazz Pharmaceuticals’ calcium channel modulator suvecaltamide in a mid-stage trial was unable to significantly lower tremor burden in patients with essential tremor, the company reported Thursday.
June 21, 2024
·
2 min read
·
Tristan Manalac
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals pl the 38th annual meeting of the Associated Professional Sleep Societies being held June 1-5, 2024, in Houston, Texas.
May 30, 2024
·
20 min read
Business
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.
May 1, 2024
·
30 min read
Drug Development
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
June 20, 2024
·
6 min read
Business
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
February 21, 2024
·
4 min read
1 of 26,528
Next
